Nikon to Distribute SVCell with its Biostation CT
SVision announced this week that Nikon will begin distributing SVision’s SVCell together with Nikon’s BioStation CT, a fully integrated cell culture observation and monitoring system.
For this purpose, SVCell will be sold under the Nikon brand using the name “CT Analysis Software SV.” The software will be used to quantitatively analyze time-lapse, phase, and fluorescence images acquired on the BioStation CT.
Millipore, Abeome Collaborate on HESCA-1 Development, Distribution
Millipore this week announced its collaboration with Abeomeon the development and distribution of the Human Embryonic Stem Cell Antigen-1 (HESCA-1) antibody.
The antibody was developed by Abeome in conjunction with Novocell. Millipore will market and distribute HESCA-1 to the research community.
According to Millipore, HESCA-1 is a previously unidentified marker for the analysis of pluripotent stem cells in immunocytochemistry and other immunological techniques. HESCA-1 targets a cell surface protein that is potentially a unique antigen expressed by human embryonic stem cells. The antigen is present in five hES cell lines, but does not appear to be expressed on differentiated or feeder cell types.
Galapagos and CFFT Agreement Worth Up to $8.1M
Galapagos and Cystic Fibrosis Foundation Therapeutics, the non-profit affiliate of the Cystic Fibrosis Foundation, this week announced a collaboration aimed at discovering new treatments for cystic fibrosis. According to Galapagos and CFFT, this agreement is worth up to €5.5 million ($8.1 million) for Galapagos.
Specifically, the collaboration aims to screen patient-derived cells to identify small molecules derived from natural sources that improve the function of the defective cystic fibrosis transmembrane conductance regulator protein found in cystic fibrosis patients.
Under the terms of the agreement, Galapagos stands to receive up to €1.6 million ($2.4 million) in upfront and research fees over the next two years, and up to €3.8 million ($5.7 million) in success-based milestone payments, should certain clinical development criteria be met.
Graffinity, Pfizer Ink Second Drug Discovery Deal
Graffinity Pharmaceuticals has entered into its second drug discovery collaboration with Pfizer, Graffinity announced this week.
Under the terms of the agreement, Graffinity will provide Pfizer with access to its proprietary, fragment-based screening technology for use in screening Pfizer drug targets. In addition, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of novel small-molecule hits against a number of drug targets.
Financial details of the transaction were not disclosed.